Oral dnaJP1 - Adeona Pharmaceuticals
Alternative Names: AT-001; dnaJ peptide; dnaJP1Latest Information Update: 02 Oct 2021
At a glance
- Originator University of California, San Diego
- Developer Adeona Pharmaceuticals
- Class Antirheumatics; Immunotherapies; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 31 Mar 2011 Discontinued - Phase-II for Rheumatoid arthritis in USA (PO)
- 30 Nov 2010 Adeona Pharmaceuticals' dnaJP1 is available for licensing as of 30 Nov 2010. http://www.adeonapharma.com/dnajp1.php
- 30 Sep 2009 Oral dnaJP1 is available for licensing worldwide (http://www.adeonapharma.com)